医疗保健服务行业_2026年展望_47页_4mb

Healthcare Services 2026 Outlook Summary

Core Content and Key Themes

The 2026 outlook for the healthcare services sector is characterized by a potential for margin improvement and policy clarity, which are expected to create a positive backdrop for the industry. The focus is on Managed Care, Pharmaceutical Distributors, Labs, and Hospitals & Facilities, with the latter two benefiting from structural shifts and improved operating conditions post-pandemic.

Main Views and Key Information

Managed Care

• Outlook: Most MCOs are expected to reach trough earnings in 2025 or 2026, with potential for upward revisions in 2027/2028.
• Drivers: Medicare Advantage (MA) is a key margin upside driver, while Medicaid and ACA Exchanges remain areas of investor skepticism.
• Regulatory Context: Policy uncertainty around 2026 midterms may lead to gridlock, limiting major policy changes outside of CMS rulemaking.
• Top Picks: UnitedHealth (UNH), CVS Health (CVS), and Alignment Healthcare (ALHC) are highlighted as "clean" stories with strong growth potential.
• Cigna (CI): Expected to face margin pressure due to PBM transition to a rebate-free model, but remains a constructive opportunity with long-term structural benefits.

Pharmaceutical Distributors

• Outlook: Strong fundamentals with stable generic pricing, MSO growth, and a robust specialty pipeline.
• Top Picks: McKesson (MCK) and Cencora (COR) are preferred due to their strong specialty businesses and value-added services.
• Capital Deployment: Distributors led M&A activity in 2025, with a shift towards integration and organic investment in MSO capabilities in 2026.

Labs

• Outlook: Strong demand in diagnostics and improved pricing traction support above historical organic growth rates.
• Progress: Positive developments on PAMA resolution and the RESULTS Act are expected to act as catalysts.
• Top Picks: Labcorp (LH) is preferred over DGX due to its more stable valuation and focus on margin expansion.

Hospitals & Facilities

• Outlook: Steady demand with some margin pressure from regulatory changes and elevated medical expenses.
• Top Picks: Tenet Healthcare (THC) is favored for its exposure to the ASC (Ambulatory Surgical Center) market and its favorable risk/reward setup.
• Concentra (CON): Expected to benefit from favorable demand trends and lower reimbursement risk due to regulatory insulation.

Investment Opportunities

Cleaner Setups

• UnitedHealth (UNH): On track for accelerated earnings growth with MA margin improvements.
• CVS Health (CVS): Strong performance in 2025 with disciplined messaging and updated LRP for mid-teens EPS growth through 2028.
• Alignment Healthcare (ALHC): Clean way to play MA with continued share gains and margin improvements.
• McKesson (MCK): Continued momentum in two new segments, with acquisitions supporting growth.
• Cencora (COR): Strategic reorganization enables focus on core and specialty operations, with organic growth visibility.
• Concentra (CON): Favorable demand and lower reimbursement risk, with focus on integration and de-leveraging.
• PACS Group (PACS): Favorable consolidation story with upside from M&A and embedded earnings.

Attractive Opportunities with Moving Pieces

• Cigna (CI): Transition year due to PBM changes, but long-term structural benefits remain.
• Option Care Health (OPCH): Strong Rx/specialty utilization but faces uncertainty due to Stelara headwinds.
• Labcorp (LH): Proactive divestiture of non-core revenues and potential for margin expansion.
• Tenet Healthcare (THC): Favorable exposure to ASCs and potential for improved FCF generation.

Capital Deployment Priorities

• Distributors: Focused on integration and organic investment in MSO capabilities, with continued interest in tuck-in deals.
• Labs: Expected to see increased M&A activity as health systems/hospitals streamline operations.
• MCOs: Likely to conserve capital in 2026, prioritizing deleveraging and maintaining dividend/buyback frameworks.

Notable Transactions (2024-2025)

Summary of Key Metrics and Analyst Views